Marcan buys remaining Mantra Pharma preferred shares for CAD 50 million

Listed Co AcquisitionStrategic Transactions View source PDF

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.3%1-day move

₹1859.00

prior close

₹1844.60

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.0+0.2+0.0+0.2-1.3-0.8-2.6-2.7-2.6-2.5+1.3———

Up moveDown movePending

AI summary

Marcan Pharmaceuticals Inc, Emcure's subsidiary, signed agreements on July 2, 2026 to acquire all Class E Special Shares in Mantra Pharma Inc, its Canadian step-down subsidiary, for CAD 50 million cash. Mantra remains 100 percent owned by Marcan after the deal. Mantra distributes prescription drugs and natural health products in Canada, with FY26 turnover of CAD 96.67 million versus CAD 81.01 million in FY25. It is a related party transaction between wholly-owned subsidiaries, done at arms length, expected to complete on July 3, 2026.

Likely market impact

Internal consolidation of 100 percent ownership in Mantra Pharma, a growing Canadian distribution arm; no change in overall group control.